Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY) from its SEC filings: 2025 revenue $15.4 million (+53% vs the year before), net margin -1801%, free cash flow -$235.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $15.4 million |
| Revenue growth | +53% |
| Net income | -$276.5 million |
| Net margin | -1800.6% |
| Free cash flow | -$235.9 million |
| Diluted EPS | $-1.61 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -48% |
| Cash | $121.2 million |
| Share count, 1 year | +27% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.